Top

Published in:

01-10-2008 | Laboratory Research

Mechanisms Driving Local Breast Cancer Recurrence in a Model of Breast-Conserving Surgery

Authors: Myles J. Smith, MRCSI, PhD, Aedín C. Culhane, PhD, Shane Killeen, MRCSI, MD, Maura A. Kelly, MRCSI, Jiang H. Wang, PhD, Thomas G. Cotter, D. Phil, Henry P. Redmond, MCh, FRCSI

Published in: Annals of Surgical Oncology | Issue 10/2008

Abstract

Objective

We aimed to identify mechanisms driving local recurrence in a model of breast-conserving surgery (BCS) for breast cancer.

Background

Breast cancer recurrence after BCS remains a clinically significant, but poorly understood problem. We have previously reported that recurrent colorectal tumours demonstrate altered growth dynamics, increased metastatic burden and resistance to apoptosis, mediated by upregulation of phosphoinositide-3-kinase/Akt (PI3K/Akt). We investigated whether similar characteristics were evident in a model of locally recurrent breast cancer.

Methods

Tumours were generated by orthotopic inoculation of 4T1 cells in two groups of female Balb/c mice and cytoreductive surgery performed when mean tumour size was above 150 mm³. Local recurrence was observed and gene expression was examined using Affymetrix GeneChips in primary and recurrent tumours. Differential expression was confirmed with quantitative real-time polymerase chain reaction (qRT-PCR). Phosphorylation of Akt was assessed using Western immunoblotting. An ex vivo heat shock protein (HSP)-loaded dendritic cell vaccine was administered in the perioperative period.

Results

We observed a significant difference in the recurrent 4T1 tumour volume and growth rate (p < 0.05). Gene expression studies suggested roles for the PI3K/Akt system and local immunosuppression driving the altered growth kinetics. We demonstrated that perioperative vaccination with an ex vivo HSP-loaded dendritic cell vaccine abrogated recurrent tumour growth in vivo (p = 0.003 at day 15).

Conclusion

Investigating therapies which target tumour survival pathways such as PI3K/Akt and boost immune surveillance in the perioperative period may be useful adjuncts to contemporary breast cancer treatment.

Fisher B, Anderson S, Bryant J et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002; 347:1233–41.PubMedCrossRef

Vicini FA, Kestin L, Huang R et al. Does local recurrence affect the rate of distant metastases and survival in patients with early-stage breast carcinoma treated with breast-conserving therapy? Cancer 2003; 97:910–9.PubMedCrossRef

Brooks JP, Danforth DN, Albert P et al. Early ipsilateral breast tumor recurrences after breast conservation affect survival: an analysis of the National Cancer Institute randomized trial. Int J Radiat Oncol Biol Phys 2005; 62:785–9.PubMed

Jatoi I, Tsimelzon A, Weiss H et al. Hazard rates of recurrence following diagnosis of primary breast cancer. Breast Cancer Res Treat 2005; 89:173–8.PubMedCrossRef

Early Breast Cancer Trialists’ Collaborative Group. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Lancet 2000; 355:1757–70

Ramaswamy S, Ross KN, Lander ES et al. A molecular signature of metastasis in primary solid tumors. Nat Genet 2003; 33:49–54.PubMedCrossRef

van’t Veer LJ, Dai H, van de Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415:530–6.CrossRef

van de Vijver MJ, He YD, van’t Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347:1999–2009.PubMedCrossRef

Wang Y, Klijn JG, Zhang Y et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005; 365:671–9.PubMed

10.

Minn AJ, Gupta GP, Siegel PM et al. Genes that mediate breast cancer metastasis to lung. Nature 2005; 436:518–24.PubMedCrossRef

11.

Nuyten DS, Kreike B, Hart AA et al. Predicting a local recurrence after breast-conserving therapy by gene expression profiling. Breast Cancer Res 2006; 8:R62.PubMedCrossRef

12.

Chang HY, Nuyten DS, Sneddon JB et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci U S A 2005; 102:3738–43.PubMedCrossRef

13.

Coffey JC, Wang JH, Smith MJ, et al. Phosphoinositide 3-kinase accelerates postoperative tumor growth by inhibiting apoptosis and enhancing resistance to chemotherapy-induced apoptosis. Novel role for an old enemy. J Biol Chem 2005; 280:20968–77.PubMedCrossRef

14.

Pulaski BA, Ostrand-Rosenberg S. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res 1998; 58:1486–93.PubMed

15.

Curtin JF, Cotter TG. JNK regulates HIPK3 expression and promotes resistance to Fas-mediated apoptosis in DU 145 prostate carcinoma cells. J Biol Chem 2004; 279:17090–100.PubMedCrossRef

16.

Butte A. The use and analysis of microarray data. Nat Rev Drug Discov 2002; 1:951–60.PubMedCrossRef

17.

Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001; 25:402–8.PubMedCrossRef

18.

Radonic A, Thulke S, Mackay IM et al. Guideline to reference gene selection for quantitative real-time PCR. Biochem Biophys Res Commun 2004; 313:856–62.PubMedCrossRef

19.

Shilling DA, Smith MJ, Tyther R et al. Salmonella typhimurium stimulation combined with tumour-derived heat shock proteins induces potent dendritic cell anti-tumour responses in a murine model. Clin Exp Immunol 2007; 149:109–16.PubMed

20.

Al-Shahrour F, Diaz-Uriarte R, Dopazo J. FatiGO: a web tool for finding significant associations of Gene Ontology terms with groups of genes. Bioinformatics 2004; 20:578–80.PubMedCrossRef

21.

Khatri P, Sellamuthu S, Malhotra P et al. Recent additions and improvements to the Onto-Tools. Nucleic Acids Res 2005; 33(Web Server issue):W762–5.PubMedCrossRef

22.

Rajeevan MS, Vernon SD, Taysavang N et al. Validation of array-based gene expression profiles by real-time (kinetic) RT-PCR. J Mol Diagn 2001; 3:26–31.PubMed

23.

Holland R, Veling SH, Mravunac M et al. Histological multifocality of Tis, T1-2 breast carcinomas. Implications for clinical trials of breast-conserving surgery. Cancer 1985; 56:979–90.PubMedCrossRef

24.

Clare SE, Nakhlis F, Panetta JC. Molecular biology of breast cancer metastasis. The use of mathematical models to determine relapse and to predict response to chemotherapy in breast cancer. Breast Cancer Res 2000; 2:430–5.PubMedCrossRef

25.

Coffey JC, Wang JH, Smith MJ et al. Excisional surgery for cancer cure: therapy at a cost. Lancet Oncol 2003; 4:760–8.PubMedCrossRef

26.

van der Bilt JD, Borel Rinkes IH. Surgery and angiogenesis. Biochim Biophys Acta 2004; 1654:95–104.PubMed

27.

L’Hote CG, Thomas PH, Ganesan TS. Functional analysis of discoidin domain receptor 1: effect of adhesion on DDR1 phosphorylation. FASEB J 2002; 16:234–6.PubMed

28.

Iyengar P, Espina V, Williams TW et al. Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment. J Clin Invest 2005; 115:1163–76.PubMed

29.

Skorski T. Oncogenic tyrosine kinases and the DNA-damage response. Nat Rev Cancer 2002; 2:351–60.PubMedCrossRef

30.

Chang HY, Sneddon JB, Alizadeh AA et al. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol 2004; 2:E7.PubMedCrossRef

31.

Vestey SB, Sen C, Calder CJ et al. Activated Akt expression in breast cancer: correlation with p53, Hdm2 and patient outcome. Eur J Cancer 2005; 41:1017–25.PubMedCrossRef

32.

Stal O, Perez-Tenorio G, Akerberg L et al. Akt kinases in breast cancer and the results of adjuvant therapy. Breast Cancer Res 2003; 5:R37–44.PubMedCrossRef

33.

Kirkegaard T, Witton CJ, McGlynn LM, et al. AKT activation predicts outcome in breast cancer patients treated with tamoxifen. J Pathol 2005; 207:139–46.PubMedCrossRef

34.

Jin X, Gossett DR, Wang S et al. Inhibition of AKT survival pathway by a small molecule inhibitor in human endometrial cancer cells. Br J Cancer 2004; 91:1808–12.PubMedCrossRef

35.

Yang L, Dan HC, Sun M et al. Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res 2004; 64:4394–9.PubMedCrossRef

36.

Nahta R, Hung MC, Esteva FJ. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 2004; 64:2343–6.PubMedCrossRef

37.

Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357:539–45.PubMedCrossRef

38.

Gilboa E. The promise of cancer vaccines. Nat Rev Cancer 2004; 4:401–11.PubMedCrossRef

39.

Danna EA, Sinha P, Gilbert M et al. Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease. Cancer Res 2004; 64:2205–11.PubMedCrossRef

40.

Menoret A, Bell G. Purification of multiple heat shock proteins from a single tumor sample. J Immunol Methods 2000; 237:119–30.PubMedCrossRef

41.

Belli F, Testori A, Rivoltini L et al. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol 2002; 20:4169–80.PubMedCrossRef

42.

Mazzaferro V, Coppa J, Carrabba MG et al. Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. Clin Cancer Res 2003; 9:3235–45.PubMed

Title: Mechanisms Driving Local Breast Cancer Recurrence in a Model of Breast-Conserving Surgery
Authors: Myles J. Smith, MRCSI, PhD
Aedín C. Culhane, PhD
Shane Killeen, MRCSI, MD
Maura A. Kelly, MRCSI
Jiang H. Wang, PhD
Thomas G. Cotter, D. Phil
Henry P. Redmond, MCh, FRCSI
Publication date: 01-10-2008
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 10/2008
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-008-0037-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Mechanisms Driving Local Breast Cancer Recurrence in a Model of Breast-Conserving Surgery

Abstract

Objective

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 10/2008

Adjuvant Therapy for Adenocarcinoma of the Pancreas: Analysis of Reported Trials and Recommendations for Future Progress

Local Recurrence After Laparoscopic Radiofrequency Ablation of Liver Tumors: An Analysis of 1032 Tumors

The Outcome of Laparoscopic Radical Hysterectomy and Lymphadenectomy for Cervical Cancer: A Prospective Analysis of 295 Patients

Pretreatment Staging of Cervical Cancer: Is Imaging Better Than Palpation?

Is the “10% Rule” Equally Valid for All Subsets of Sentinel-Node-Positive Breast Cancer Patients?

Use of Gliadel (BCNU) Wafer in the Surgical Treatment of Malignant Glioma: A 10-Year Institutional Experience